Clinical trial
An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
NCT02979522 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
- Lead sponsor
- Takeda
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- September 6, 2017
- Completion date
- September 24, 2029
- Enrollment
- 59 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.